查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1807615

伴侶動物藥物市場（按動物類型、產品類型、劑型、通路、疾病和最終用戶分類）－2025-2030 年全球預測

Companion Animal Pharmaceuticals Market by Animal Type, Product Type, Formulation, Distribution Channel, Disease Condition, End User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 184 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

伴侶動物藥物市場預計到 2024 年將達到 175.3 億美元，2025 年將達到 188.5 億美元，到 2030 年將達到 272.6 億美元，複合年成長率為 7.63%。

主要市場統計數據
基準年2024年 175.3億美元
預計2025年 188.5億美元
預測年份 2030 272.6億美元
複合年成長率（%） 7.63%

為下一代伴侶動物藥物奠定基礎，以滿足寵物和馬匹不斷變化的健康需求

伴侶動物製藥產業已成為全球動物保健的重要支柱，體現了人類與寵物之間日益加深的連結。近年來，寵物飼養數量的增加、動物福利意識的增強以及獸醫學的進步，推動了對創新治療方法的需求。如今，飼主尋求的解決方案不僅能治療疾病，還能改善寵物的整體健康，這促使製造商不斷擴展產品線。同時，監管機構正在推出更為細緻的指導方針，以確保安全性和有效性，從而提高了產品開發和核准的門檻。

透過技術進步和不斷變化的監管環境，引領伴侶動物醫學格局的顛覆性發展

在技​​術創新、流行病學概況變化和法律規範不斷發展的推動下，伴侶動物製藥領域正在經歷重大變革時期。老年寵物族群中慢性病的盛行率不斷上升，這刺激了人們對長期治療方法的研究，並鼓勵人們採用緩釋性注射劑和新型生技藥品。同時，數位健康平台、遠端醫療服務和人工智慧主導的診斷技術開始影響處方行為和依從性，在獸醫和飼主之間建立一個更具互動性的生態系統。

評估2025年美國關稅調整及其對伴侶動物保健產品供應鏈的廣泛影響

2025年，美國進口關稅大幅調整，為伴侶動物藥品領域的公司帶來了新的考量。原料和成品劑型關稅的提高推高了銷售成本，迫使製造商重新考慮籌資策略和定價結構。一些供應商正在透過多元化採購網路、將生產轉移到關稅優惠的司法管轄區或加快對本地生產的投資來緩解這些壓力。

發現全面的市場區隔洞察，揭示不同的動物類型、產品、配方、通路和最終用戶動態

深入研究市場區隔，可以發現重要的細微差別，從而指南伴侶動物藥物的策略規劃。就動物類型而言，每個物種——禽類、貓科動物、犬科動物和馬科動物——都呈現出獨特的治療需求、監管途徑和產品採用率。犬科動物和貓科動物在創新重點和商業活動方面佔據主導地位，而馬科動物健康產品通常因性能和育種應用而具有溢價。禽類市場雖然相對小眾，但其預防性疫苗和特殊抗菌藥物正受到越來越多的關注。

戰略區域展望重點關注美洲、歐洲、中東和非洲地區以及亞太地區市場的需求促進因素和成長機會

區域展望凸顯了美洲、歐洲、中東和非洲以及亞太市場差異化的成長軌跡和競爭態勢。在美洲，寵物飼養趨勢和優惠的報銷制度支撐了對高階療法和新型生技藥品的強勁需求。北美市場受益於簡化的監管審查和消費者對先進療法的強烈投資意願，而拉丁美洲經濟體正在逐步擴大其獸醫基礎設施，擴大基本藥物的可及性。

透過策略舉措和合作塑造伴侶動物醫學未來的關鍵創新者和主要企業的簡介

產業領導者正在採取各種策略性舉措，以鞏固其在伴侶動物藥物領域的地位。領先的公司正在擴大研究中心，並日益注重內部生技藥品能力，以加速單株抗體和新型疫苗平台的開發。與生技公司的策略性收購和合作協議凸顯了他們對創新的動力，並加快了最先進治療的上市時間。

為伴侶動物藥物開發行業的領導者提供可行的策略建議，以推動成長和創新

產業領導者可以立即採取行動，抓住新興機會，應對關鍵挑戰。首先，優先投資先進生技藥品和精準醫療，將使其產品組合更具差異化，並滿足日益成長的針對性解決方案需求。將研發資源分配給單株抗體、下一代疫苗和基因治療平台，將使企業始終處於科學創新的前沿。

描述用於準確可靠地分析伴侶動物藥物市場動態的嚴格調查方法

本報告採用一手資料調查方法，以確保獲得可靠且穩健的見解。二手資料研究涵蓋對學術期刊、行業白皮書、監管文件和公司文獻的深入研究，旨在建立對市場動態、法律規範和技術進步的基礎理解。

總結性見解總結了主要發現並強調了對伴侶動物製藥行業的戰略意義

伴侶動物製藥產業正處於關鍵的十字路口，生技藥品的進步、疾病負擔的轉變以及消費行為的演變正在重塑競爭格局。從動物類型到最終用戶，關鍵細分領域揭示了差異化的成長路徑，而區域動態則凸顯了不同的市場成熟度和策略要務。 2025年關稅調整的累積影響凸顯了韌性供應鏈和積極主動的政策參與的重要性。

目錄

第1章：前言

第2章調查方法

第3章執行摘要

第4章 市場概述

第5章市場動態

  • 寵物擁有量的增加和寵物的人性化
  • 普及可早期發現寵物慢性疾病的家用診斷套件
  • 針對寵物遺傳疾病的口服基因治療發展迅速
  • 新型抗菌肽的出現可對抗寵物抗藥性感染疾病
  • 營養補充品組合在老年寵物健康管理中越來越受歡迎
  • 預防性寵物保健需求不斷成長
  • 電子商務和直接面對消費者的獸醫藥局的成長
  • 寵物專用藥物配方及給藥的進展
  • 擴大伴侶動物抗生素管理計畫的遠距遠端醫療處方服務
  • 製藥和生物技術公司合作推進動物基因治療

第6章 市場洞察

  • 波特五力分析
  • PESTEL分析

第7章 2025年美國關稅的累積影響

8. 伴侶動物藥物市場（依動物類型）

  • 鳥
  • 貓
  • 狗
  • 馬

9. 伴侶動物藥物市場（依產品類型）

  • 抗菌劑
    • 抗生素
    • 抗真菌藥物
    • 抗寄生蟲藥
  • 生物製藥
    • 干擾素
    • 單株抗體
    • 疫苗
  • 生長促進劑
  • 藥品和飼料添加劑
  • 製藥

10. 伴侶動物藥物市場（按劑型）

  • 注射
  • 液體
  • 修補
  • 粉末
  • 噴
  • 藥片

11. 伴侶動物藥物市場（依分銷管道）

  • 線上零售商
  • 藥局連鎖
  • 獸醫診所

12. 伴侶動物藥物市場（依疾病狀況）

  • 慢性病
  • 胃腸道問題
    • 結腸炎
    • 發炎性腸道疾病
  • 感染疾病
    • 細菌感染疾病
    • 病毒感染

13. 伴侶動物藥物市場（依最終用戶）

  • 動物收容所和救援組織
  • 寵物飼養員/訓練員
  • 寵物飼主
  • 獸醫

14.美洲伴侶動物藥物市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 阿根廷

15. 歐洲、中東和非洲伴侶動物藥物市場

  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 阿拉伯聯合大公國
  • 沙烏地阿拉伯
  • 南非
  • 丹麥
  • 荷蘭
  • 卡達
  • 芬蘭
  • 瑞典
  • 奈及利亞
  • 埃及
  • 土耳其
  • 以色列
  • 挪威
  • 波蘭
  • 瑞士

16. 亞太地區伴侶動物藥物市場

  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國
  • 印尼
  • 泰國
  • 菲律賓
  • 馬來西亞
  • 新加坡
  • 越南
  • 台灣

第17章競爭格局

  • 2024年市場佔有率分析
  • 2024年FPNV定位矩陣
  • 競爭分析
    • Alivira Animal Health Limited
    • Ashish Life Science Pvt. Ltd.
    • Boehringer Ingelheim International GmbH
    • Ceva Sante Animale
    • Chanelle Pharma
    • Dechra Pharmaceuticals PLC
    • Eco Animal Health Group PLC
    • Elanco Animal Health Incorporated
    • Endovac Animal Health, LLC
    • Hester Biosciences Limited
    • Hipra Laboratories, SA
    • Indian Immunologicals Ltd.
    • Kyoritsu Seiyaku Corporation
    • Meiji Group
    • Merck KGaA
    • Neogen Corporation
    • Norbrook Laboratories Ltd.
    • Orion Corporation
    • Phibro Animal Health Corporation
    • SkyEc Pharmaceuticals Private Limited
    • Stanex Drugs and Chemicals Pvt Ltd.
    • Tianjin Ringpu Biotechnology Co., Ltd.
    • Veko Care
    • Vetbiolix
    • Virbac SA
    • Zoetis Inc.
    • Zydus Animal Health

第18章 研究人工智慧

第19章 研究統計

第20章 研究聯絡人

第21章 研究報導

第22章 附錄

Product Code: MRR-FD3F12D52B58

The Companion Animal Pharmaceuticals Market was valued at USD 17.53 billion in 2024 and is projected to grow to USD 18.85 billion in 2025, with a CAGR of 7.63%, reaching USD 27.26 billion by 2030.

KEY MARKET STATISTICS
Base Year [2024] USD 17.53 billion
Estimated Year [2025] USD 18.85 billion
Forecast Year [2030] USD 27.26 billion
CAGR (%) 7.63%

Setting the Stage for Next Generation Companion Animal Pharmaceuticals to Address Evolving Health Needs in Pets and Equine Populations

The companion animal pharmaceuticals sector has emerged as a critical pillar in global animal health, reflecting the deepening bond between humans and their pets. In recent years, increased pet ownership, heightened awareness of animal welfare, and advances in veterinary medicine have driven the demand for innovative therapies. Owners now seek solutions that not only treat diseases but also enhance overall well-being, prompting manufacturers to expand their pipelines. Meanwhile, regulatory agencies have introduced more nuanced guidelines to ensure safety and efficacy, elevating the bar for product development and approval.

Amid these dynamics, stakeholders are navigating complex supply chains that span continents, balancing cost pressures with the imperative to maintain consistent product quality. Technological breakthroughs in biologics, targeted therapies, and digital health platforms offer new avenues for growth, yet they also demand robust R&D investments and agile commercialization strategies. Against this backdrop, the industry is challenged to anticipate shifting disease patterns, integrate novel delivery systems, and respond to evolving consumer expectations.

This executive summary distills the most significant trends reshaping the market, from transformative scientific innovations to the ripple effects of global trade policies. It provides an authoritative foundation for decision makers seeking a comprehensive understanding of the current landscape, enabling them to pinpoint strategic opportunities and chart a course toward sustainable growth.

Navigating Disruptive Transformations Reshaping the Companion Animal Pharmaceuticals Landscape Through Technological Advancements and Regulatory Evolution

The companion animal pharmaceuticals landscape is undergoing profound transformations driven by technological innovation, changing epidemiological profiles, and evolving regulatory frameworks. Increased prevalence of chronic diseases among aging pet populations has spurred research into long-term therapeutic regimens, encouraging the adoption of sustained-release injectables and novel biologics. Concurrently, digital health platforms, telemedicine services, and AI-driven diagnostics are beginning to influence prescribing behaviors and compliance, creating a more interactive ecosystem between veterinarians and pet owners.

Regulatory authorities across key markets have accelerated approval pathways for breakthrough therapies, especially those leveraging monoclonal antibodies, gene therapies, and personalized medicine approaches. These expedited processes, however, require manufacturers to invest heavily in rigorous safety and efficacy studies, raising the stakes of clinical development. Meanwhile, the demand for natural and holistic solutions has elevated interest in nutraceuticals and alternative modalities, compelling traditional pharmaceutical companies to broaden their scope.

Shifting consumer attitudes are also redefining value propositions, as pet owners increasingly prioritize convenience, transparency, and data-driven care. Subscription models for prescription renewals, home delivery of medicated feed additives, and integrated health tracking applications are reshaping distribution dynamics. In this environment of simultaneous disruption and opportunity, companies must embrace agility, foster cross-sector partnerships, and align innovation pipelines with emerging market realities to stay competitive.

Assessing the 2025 United States Tariff Adjustments and Their Far-Reaching Implications for Companion Animal Health Product Supply Chains

In 2025, sweeping adjustments to United States import tariffs have created a new calculus for companies operating in the companion animal pharmaceuticals sector. Heightened duties on raw materials and finished formulations have increased cost of goods sold, compelling manufacturers to reexamine sourcing strategies and pricing structures. Some suppliers have mitigated these pressures by diversifying their procurement networks, shifting production to tariff-friendly jurisdictions, or accelerating local manufacturing investments.

These tariff realignments have also rippled through global supply chains, as contract manufacturers and active pharmaceutical ingredient producers adapt to changing trade flows. Extended lead times and elevated freight costs have underscored the need for strategic inventory management, with several organizations adopting just-in-time models to balance stock availability against cash flow constraints. At the same time, hedging strategies and long-term supplier agreements have emerged as vital tools to stabilize margins and ensure continuity of supply.

Pricing pressures introduced by tariffs have in some cases accelerated consolidation among smaller players, as they struggle to absorb escalating expenses. Larger firms with integrated global footprints are better positioned to leverage volume advantages and internalize production costs. For decision makers, these developments underscore the importance of scenario planning, flexible manufacturing capabilities, and proactive engagement with policymakers to navigate the evolving trade environment effectively.

Unlocking Comprehensive Market Segmentation Insights That Illuminate Diverse Animal Types, Products, Formulations, Channels, and End User Dynamics

A deep dive into market segmentation reveals critical nuances that guide strategic planning across companion animal pharmaceuticals. When examining animal type, each species-whether birds, cats, dogs, or horses-exhibits distinct therapeutic requirements, regulatory pathways, and product adoption rates. Canine and feline segments dominate in terms of innovation focus and commercial activity, while equine health often commands premium pricing driven by performance and breeding applications. Avian markets remain comparatively niche but are attracting attention for preventive vaccines and specialized antimicrobials.

Exploring product type highlights the layered complexity of pharmaceutical offerings. Antimicrobials encompass antibiotics, antifungals, and antiparasitics, which address both therapeutic and prophylactic needs. Biologics, including interferons, monoclonal antibodies, and vaccines, are rapidly gaining share due to their precision and safety profiles. Growth promoters and medicated feed additives continue to play a vital role in livestock-adjacent segments, while traditional pharmaceutical drugs span a broad spectrum of small-molecule therapies.

Formulation preferences further influence market entry strategies, as injectables, liquids, patches, powders, sprays, and tablets each present unique stability and administration considerations. Distribution channel analysis underscores the rise of online retailers alongside established pharmacy chains and veterinary clinics, reshaping access points and influencing margin structures. Disease condition analysis shows chronic conditions accounting for sustained treatment regimens, gastrointestinal issues such as colitis and inflammatory bowel disease driving demand for targeted interventions, and infectious diseases-bacterial and viral-inspiring robust vaccine pipelines. Finally, the end user landscape, comprising animal shelters and rescue organizations, pet breeders and trainers, individual pet owners, and veterinary professionals, dictates specific marketing and education approaches to maximize engagement and adherence.

Revealing Strategic Regional Perspectives Highlighting Demand Drivers and Growth Opportunities Across the Americas, EMEA, and Asia-Pacific Markets

Regional perspectives offer a window into differentiated growth trajectories and competitive dynamics across the Americas, EMEA, and Asia-Pacific. In the Americas, strong pet ownership trends and favorable reimbursement frameworks support robust demand for premium therapeutics and novel biologics. North American markets benefit from streamlined regulatory reviews and high consumer willingness to invest in advanced treatments, while Latin American economies are gradually expanding veterinary infrastructure and broadening access to essential medicines.

Within Europe, Middle East and Africa, regulatory harmonization across the European Union and collaborative initiatives in the Middle East have created a fertile environment for innovation. Growing investments in local biomanufacturing and increasing recognition of animal welfare standards are driving product launches and market penetration. In Africa, strategic partnerships with international organizations are enhancing vaccination campaigns and disease surveillance, laying the groundwork for future pharmaceutical growth.

The Asia-Pacific region is characterized by divergent market maturity, with established markets like Japan and Australia leading in biologics adoption and digital health integration. Rapidly developing economies in Southeast Asia and South Asia are witnessing rising pet ownership and government initiatives to bolster veterinary services. Manufacturers are prioritizing capacity expansions and regulatory alignment to tap into this heterogeneous yet high-potential market landscape.

Profiling Leading Innovators and Key Players Shaping the Future of Companion Animal Pharmaceuticals Through Strategic Initiatives and Collaborations

Industry leaders are deploying a range of strategic initiatives to fortify their positions in the companion animal pharmaceuticals arena. Major players are increasingly focusing on in-house biologics capabilities, expanding research centers to expedite the development of monoclonal antibodies and novel vaccine platforms. Strategic acquisitions and collaborative agreements with biotechnology firms underscore an appetite for innovation and an acceleration of time-to-market for cutting-edge therapies.

Several key organizations have prioritized sustainability, integrating eco-friendly manufacturing processes and reducing carbon footprints within their supply chains. At the same time, digital transformation efforts, such as data analytics for real-world evidence and AI-driven drug discovery, are reshaping R&D paradigms. Partnerships between pharmaceutical companies and veterinary telehealth providers are creating seamless patient journeys, boosting adherence and enabling remote monitoring of treatment outcomes.

These market leaders also demonstrate agility in response to regulatory shifts, maintaining dedicated teams for policy advocacy and compliance. By fostering open dialogue with regulatory bodies, they secure early insight into changing guidelines, ensuring their product pipelines align with emerging requirements. Together, these strategic moves highlight a proactive approach to innovation, sustainability, and stakeholder engagement that will define success in the evolving companion animal pharmaceuticals ecosystem.

Delivering Actionable Strategic Recommendations to Propel Growth and Innovation for Industry Leaders in Companion Animal Pharmaceutical Development

Industry leaders can take immediate action to harness emerging opportunities and address critical challenges. First, prioritizing investment in advanced biologics and precision therapies will differentiate portfolios and meet growing demand for targeted solutions. Allocating R&D resources to monoclonal antibodies, next-generation vaccines, and gene therapy platforms can position organizations at the forefront of scientific innovation.

Simultaneously, optimizing global supply chains through diversification of manufacturing footprints will mitigate risks associated with escalating tariffs and geopolitical uncertainties. Developing regional production hubs and forging long-term agreements with key suppliers can enhance resilience, reduce lead times, and stabilize cost structures. Leveraging digital supply chain management tools will further improve real-time visibility and decision making.

A third imperative involves deepening customer engagement by integrating digital health solutions and tailored educational programs. Collaborations with telehealth providers, interactive mobile applications, and virtual training for veterinary professionals can elevate brand loyalty and adherence. Finally, aligning corporate sustainability goals with operational practices-such as reducing single-use plastics in packaging or adopting green chemistry principles-will resonate with conscientious consumers and bolster corporate reputation. By executing these strategic recommendations, organizations will be well-equipped to drive growth, enhance innovation, and secure long-term competitive advantage.

Explaining Rigorous Research Methodologies Employed to Analyze Market Dynamics in Companion Animal Pharmaceuticals with Precision and Credibility

The research methodology underpinning this report integrates a blend of primary and secondary approaches to ensure robust and credible insights. Secondary research involved exhaustive reviews of academic journals, industry whitepapers, regulatory filings, and company literature to establish a foundational understanding of market dynamics, regulatory frameworks, and technological advancements.

Primary research complemented these efforts, featuring in-depth interviews with veterinary specialists, pharmaceutical executives, and key opinion leaders. These expert dialogues provided granular perspectives on product development pipelines, commercialization challenges, and evolving end user preferences. Survey data collected from veterinary clinics, pet owners, and distribution partners enriched the analysis of adoption trends and channel performance.

Data triangulation and validation processes were applied throughout to reconcile diverse inputs and fortify the accuracy of findings. Quantitative analyses of historical shipment volumes, trade data, and patent filings were cross-referenced with qualitative insights to derive nuanced interpretations. This rigorous methodology ensures that strategic recommendations are grounded in empirical evidence and aligned with real-world industry conditions.

Concluding Insights That Synthesize Key Findings and Emphasize the Strategic Implications for the Companion Animal Pharmaceutical Industry

The companion animal pharmaceuticals industry stands at a pivotal juncture, where advancements in biologics, shifting disease burdens, and evolving consumer behaviors converge to reshape competitive landscapes. Key segmentations-from animal type to end user-reveal differentiated pathways for growth, while regional dynamics highlight diverse market maturity and strategic imperatives. The cumulative impact of 2025 tariff adjustments underscores the importance of resilient supply chains and proactive policy engagement.

Leading companies are setting the bar through targeted R&D investments, strategic collaborations, and digital health initiatives that enhance patient outcomes and streamline operations. Actionable recommendations emphasize the critical need for biologics innovation, supply chain diversification, digital integration, and sustainability commitments. These strategic priorities will empower industry participants to navigate uncertainty and capitalize on emerging opportunities.

As decision makers chart their course forward, this analysis offers a comprehensive roadmap grounded in rigorous research and expert insight. By synthesizing core findings and prioritizing strategic execution, organizations can secure a competitive edge and contribute to the advancement of companion animal health worldwide.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Market Sizing & Forecasting

5. Market Dynamics

  • 5.1. Rising pet ownership and humanization of companion animals
  • 5.2. Growth of at-home diagnostic kits enabling early detection of chronic conditions in pets
  • 5.3. Surge in development of oral gene therapies targeting hereditary disorders in pets
  • 5.4. Emergence of novel antimicrobial peptides to combat resistant infections in companion animals
  • 5.5. Rising prevalence of nutraceutical combinations in senior pet health management
  • 5.6. Increased demand for preventive healthcare in pets
  • 5.7. Growth of eCommerce and direct-to-consumer veterinary pharmacies
  • 5.8. Advancements in pet-specific drug formulations and delivery methods
  • 5.9. Expansion of telemedicine prescribing services for companion animal antibiotic stewardship programs
  • 5.10. Collaborative partnerships between pharmaceutical and biotech firms to advance animal gene therapies

6. Market Insights

  • 6.1. Porter's Five Forces Analysis
  • 6.2. PESTLE Analysis

7. Cumulative Impact of United States Tariffs 2025

8. Companion Animal Pharmaceuticals Market, by Animal Type

  • 8.1. Introduction
  • 8.2. Birds
  • 8.3. Cats
  • 8.4. Dogs
  • 8.5. Horses

9. Companion Animal Pharmaceuticals Market, by Product Type

  • 9.1. Introduction
  • 9.2. Antimicrobials
    • 9.2.1. Antibiotics
    • 9.2.2. Antifungals
    • 9.2.3. Antiparasitics
  • 9.3. Biologics
    • 9.3.1. Interferons
    • 9.3.2. Monoclonal Antibodies
    • 9.3.3. Vaccines
  • 9.4. Growth Promoters
  • 9.5. Medicated Feed Additives
  • 9.6. Pharmaceutical Drugs

10. Companion Animal Pharmaceuticals Market, by Formulation

  • 10.1. Introduction
  • 10.2. Injectables
  • 10.3. Liquids
  • 10.4. Patches
  • 10.5. Powders
  • 10.6. Sprays
  • 10.7. Tablets

11. Companion Animal Pharmaceuticals Market, by Distribution Channel

  • 11.1. Introduction
  • 11.2. Online Retailers
  • 11.3. Pharmacy Chains
  • 11.4. Veterinary Clinics

12. Companion Animal Pharmaceuticals Market, by Disease Condition

  • 12.1. Introduction
  • 12.2. Chronic Conditions
  • 12.3. Gastrointestinal Issues
    • 12.3.1. Colitis
    • 12.3.2. Inflammatory Bowel Disease
  • 12.4. Infectious Diseases
    • 12.4.1. Bacterial Infections
    • 12.4.2. Viral Infections

13. Companion Animal Pharmaceuticals Market, by End User

  • 13.1. Introduction
  • 13.2. Animal Shelters & Rescue Organizations
  • 13.3. Pet Breeders / Trainers
  • 13.4. Pet Owners
  • 13.5. Veterinarians

14. Americas Companion Animal Pharmaceuticals Market

  • 14.1. Introduction
  • 14.2. United States
  • 14.3. Canada
  • 14.4. Mexico
  • 14.5. Brazil
  • 14.6. Argentina

15. Europe, Middle East & Africa Companion Animal Pharmaceuticals Market

  • 15.1. Introduction
  • 15.2. United Kingdom
  • 15.3. Germany
  • 15.4. France
  • 15.5. Russia
  • 15.6. Italy
  • 15.7. Spain
  • 15.8. United Arab Emirates
  • 15.9. Saudi Arabia
  • 15.10. South Africa
  • 15.11. Denmark
  • 15.12. Netherlands
  • 15.13. Qatar
  • 15.14. Finland
  • 15.15. Sweden
  • 15.16. Nigeria
  • 15.17. Egypt
  • 15.18. Turkey
  • 15.19. Israel
  • 15.20. Norway
  • 15.21. Poland
  • 15.22. Switzerland

16. Asia-Pacific Companion Animal Pharmaceuticals Market

  • 16.1. Introduction
  • 16.2. China
  • 16.3. India
  • 16.4. Japan
  • 16.5. Australia
  • 16.6. South Korea
  • 16.7. Indonesia
  • 16.8. Thailand
  • 16.9. Philippines
  • 16.10. Malaysia
  • 16.11. Singapore
  • 16.12. Vietnam
  • 16.13. Taiwan

17. Competitive Landscape

  • 17.1. Market Share Analysis, 2024
  • 17.2. FPNV Positioning Matrix, 2024
  • 17.3. Competitive Analysis
    • 17.3.1. Alivira Animal Health Limited
    • 17.3.2. Ashish Life Science Pvt. Ltd.
    • 17.3.3. Boehringer Ingelheim International GmbH
    • 17.3.4. Ceva Sante Animale
    • 17.3.5. Chanelle Pharma
    • 17.3.6. Dechra Pharmaceuticals PLC
    • 17.3.7. Eco Animal Health Group PLC
    • 17.3.8. Elanco Animal Health Incorporated
    • 17.3.9. Endovac Animal Health, LLC
    • 17.3.10. Hester Biosciences Limited
    • 17.3.11. Hipra Laboratories, S.A.
    • 17.3.12. Indian Immunologicals Ltd.
    • 17.3.13. Kyoritsu Seiyaku Corporation
    • 17.3.14. Meiji Group
    • 17.3.15. Merck KGaA
    • 17.3.16. Neogen Corporation
    • 17.3.17. Norbrook Laboratories Ltd.
    • 17.3.18. Orion Corporation
    • 17.3.19. Phibro Animal Health Corporation
    • 17.3.20. SkyEc Pharmaceuticals Private Limited
    • 17.3.21. Stanex Drugs and Chemicals Pvt Ltd.
    • 17.3.22. Tianjin Ringpu Biotechnology Co., Ltd.
    • 17.3.23. Veko Care
    • 17.3.24. Vetbiolix
    • 17.3.25. Virbac S.A.
    • 17.3.26. Zoetis Inc.
    • 17.3.27. Zydus Animal Health

18. ResearchAI

19. ResearchStatistics

20. ResearchContacts

21. ResearchArticles

22. Appendix

LIST OF FIGURES

  • FIGURE 1. COMPANION ANIMAL PHARMACEUTICALS MARKET RESEARCH PROCESS
  • FIGURE 2. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 3. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 4. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANIMAL TYPE, 2024 VS 2030 (%)
  • FIGURE 6. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANIMAL TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
  • FIGURE 8. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY FORMULATION, 2024 VS 2030 (%)
  • FIGURE 10. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY FORMULATION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
  • FIGURE 12. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 13. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISEASE CONDITION, 2024 VS 2030 (%)
  • FIGURE 14. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISEASE CONDITION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 15. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
  • FIGURE 16. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 17. AMERICAS COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 18. AMERICAS COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 19. UNITED STATES COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
  • FIGURE 20. UNITED STATES COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 23. ASIA-PACIFIC COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 24. ASIA-PACIFIC COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 25. COMPANION ANIMAL PHARMACEUTICALS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 26. COMPANION ANIMAL PHARMACEUTICALS MARKET, FPNV POSITIONING MATRIX, 2024
  • FIGURE 27. COMPANION ANIMAL PHARMACEUTICALS MARKET: RESEARCHAI
  • FIGURE 28. COMPANION ANIMAL PHARMACEUTICALS MARKET: RESEARCHSTATISTICS
  • FIGURE 29. COMPANION ANIMAL PHARMACEUTICALS MARKET: RESEARCHCONTACTS
  • FIGURE 30. COMPANION ANIMAL PHARMACEUTICALS MARKET: RESEARCHARTICLES

LIST OF TABLES

  • TABLE 1. COMPANION ANIMAL PHARMACEUTICALS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, 2025-2030 (USD MILLION)
  • TABLE 5. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 7. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 9. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANIMAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANIMAL TYPE, 2025-2030 (USD MILLION)
  • TABLE 11. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY BIRDS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY BIRDS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 13. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY CATS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY CATS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 15. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY DOGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY DOGS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 17. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY HORSES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY HORSES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 19. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 21. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANTIMICROBIALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANTIMICROBIALS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 23. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 25. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANTIFUNGALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANTIFUNGALS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 27. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANTIPARASITICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANTIPARASITICS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 29. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANTIMICROBIALS, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANTIMICROBIALS, 2025-2030 (USD MILLION)
  • TABLE 31. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY BIOLOGICS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 33. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY INTERFERONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY INTERFERONS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 35. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 37. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY VACCINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY VACCINES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 39. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY BIOLOGICS, 2025-2030 (USD MILLION)
  • TABLE 41. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY GROWTH PROMOTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY GROWTH PROMOTERS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 43. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY MEDICATED FEED ADDITIVES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY MEDICATED FEED ADDITIVES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 45. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY PHARMACEUTICAL DRUGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY PHARMACEUTICAL DRUGS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 47. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
  • TABLE 49. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY INJECTABLES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY INJECTABLES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 51. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY LIQUIDS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY LIQUIDS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 53. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY PATCHES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY PATCHES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 55. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY POWDERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY POWDERS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 57. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY SPRAYS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY SPRAYS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 59. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY TABLETS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY TABLETS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 61. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 63. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY ONLINE RETAILERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY ONLINE RETAILERS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 65. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY PHARMACY CHAINS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY PHARMACY CHAINS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 67. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY VETERINARY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY VETERINARY CLINICS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 69. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISEASE CONDITION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISEASE CONDITION, 2025-2030 (USD MILLION)
  • TABLE 71. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY CHRONIC CONDITIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY CHRONIC CONDITIONS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 73. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY GASTROINTESTINAL ISSUES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY GASTROINTESTINAL ISSUES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 75. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY COLITIS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY COLITIS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 77. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 79. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY GASTROINTESTINAL ISSUES, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY GASTROINTESTINAL ISSUES, 2025-2030 (USD MILLION)
  • TABLE 81. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 83. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY BACTERIAL INFECTIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY BACTERIAL INFECTIONS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 85. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY VIRAL INFECTIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY VIRAL INFECTIONS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 87. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
  • TABLE 89. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 91. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANIMAL SHELTERS & RESCUE ORGANIZATIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANIMAL SHELTERS & RESCUE ORGANIZATIONS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 93. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY PET BREEDERS / TRAINERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY PET BREEDERS / TRAINERS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 95. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY PET OWNERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY PET OWNERS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 97. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY VETERINARIANS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY VETERINARIANS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 99. AMERICAS COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANIMAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 100. AMERICAS COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANIMAL TYPE, 2025-2030 (USD MILLION)
  • TABLE 101. AMERICAS COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 102. AMERICAS COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 103. AMERICAS COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANTIMICROBIALS, 2018-2024 (USD MILLION)
  • TABLE 104. AMERICAS COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANTIMICROBIALS, 2025-2030 (USD MILLION)
  • TABLE 105. AMERICAS COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
  • TABLE 106. AMERICAS COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY BIOLOGICS, 2025-2030 (USD MILLION)
  • TABLE 107. AMERICAS COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 108. AMERICAS COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
  • TABLE 109. AMERICAS COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 110. AMERICAS COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 111. AMERICAS COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISEASE CONDITION, 2018-2024 (USD MILLION)
  • TABLE 112. AMERICAS COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISEASE CONDITION, 2025-2030 (USD MILLION)
  • TABLE 113. AMERICAS COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY GASTROINTESTINAL ISSUES, 2018-2024 (USD MILLION)
  • TABLE 114. AMERICAS COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY GASTROINTESTINAL ISSUES, 2025-2030 (USD MILLION)
  • TABLE 115. AMERICAS COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 116. AMERICAS COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
  • TABLE 117. AMERICAS COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 118. AMERICAS COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 119. AMERICAS COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. AMERICAS COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 121. UNITED STATES COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANIMAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 122. UNITED STATES COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANIMAL TYPE, 2025-2030 (USD MILLION)
  • TABLE 123. UNITED STATES COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 124. UNITED STATES COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 125. UNITED STATES COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANTIMICROBIALS, 2018-2024 (USD MILLION)
  • TABLE 126. UNITED STATES COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANTIMICROBIALS, 2025-2030 (USD MILLION)
  • TABLE 127. UNITED STATES COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
  • TABLE 128. UNITED STATES COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY BIOLOGICS, 2025-2030 (USD MILLION)
  • TABLE 129. UNITED STATES COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 130. UNITED STATES COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
  • TABLE 131. UNITED STATES COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 132. UNITED STATES COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 133. UNITED STATES COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISEASE CONDITION, 2018-2024 (USD MILLION)
  • TABLE 134. UNITED STATES COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISEASE CONDITION, 2025-2030 (USD MILLION)
  • TABLE 135. UNITED STATES COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY GASTROINTESTINAL ISSUES, 2018-2024 (USD MILLION)
  • TABLE 136. UNITED STATES COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY GASTROINTESTINAL ISSUES, 2025-2030 (USD MILLION)
  • TABLE 137. UNITED STATES COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 138. UNITED STATES COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
  • TABLE 139. UNITED STATES COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 140. UNITED STATES COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 141. UNITED STATES COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
  • TABLE 142. UNITED STATES COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
  • TABLE 143. CANADA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANIMAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 144. CANADA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANIMAL TYPE, 2025-2030 (USD MILLION)
  • TABLE 145. CANADA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 146. CANADA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 147. CANADA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANTIMICROBIALS, 2018-2024 (USD MILLION)
  • TABLE 148. CANADA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANTIMICROBIALS, 2025-2030 (USD MILLION)
  • TABLE 149. CANADA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
  • TABLE 150. CANADA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY BIOLOGICS, 2025-2030 (USD MILLION)
  • TABLE 151. CANADA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 152. CANADA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
  • TABLE 153. CANADA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 154. CANADA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 155. CANADA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISEASE CONDITION, 2018-2024 (USD MILLION)
  • TABLE 156. CANADA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISEASE CONDITION, 2025-2030 (USD MILLION)
  • TABLE 157. CANADA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY GASTROINTESTINAL ISSUES, 2018-2024 (USD MILLION)
  • TABLE 158. CANADA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY GASTROINTESTINAL ISSUES, 2025-2030 (USD MILLION)
  • TABLE 159. CANADA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 160. CANADA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
  • TABLE 161. CANADA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 162. CANADA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 163. MEXICO COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANIMAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 164. MEXICO COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANIMAL TYPE, 2025-2030 (USD MILLION)
  • TABLE 165. MEXICO COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 166. MEXICO COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 167. MEXICO COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANTIMICROBIALS, 2018-2024 (USD MILLION)
  • TABLE 168. MEXICO COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANTIMICROBIALS, 2025-2030 (USD MILLION)
  • TABLE 169. MEXICO COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
  • TABLE 170. MEXICO COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY BIOLOGICS, 2025-2030 (USD MILLION)
  • TABLE 171. MEXICO COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 172. MEXICO COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
  • TABLE 173. MEXICO COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 174. MEXICO COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 175. MEXICO COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISEASE CONDITION, 2018-2024 (USD MILLION)
  • TABLE 176. MEXICO COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISEASE CONDITION, 2025-2030 (USD MILLION)
  • TABLE 177. MEXICO COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY GASTROINTESTINAL ISSUES, 2018-2024 (USD MILLION)
  • TABLE 178. MEXICO COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY GASTROINTESTINAL ISSUES, 2025-2030 (USD MILLION)
  • TABLE 179. MEXICO COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 180. MEXICO COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
  • TABLE 181. MEXICO COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 182. MEXICO COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 183. BRAZIL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANIMAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 184. BRAZIL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANIMAL TYPE, 2025-2030 (USD MILLION)
  • TABLE 185. BRAZIL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 186. BRAZIL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 187. BRAZIL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANTIMICROBIALS, 2018-2024 (USD MILLION)
  • TABLE 188. BRAZIL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANTIMICROBIALS, 2025-2030 (USD MILLION)
  • TABLE 189. BRAZIL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
  • TABLE 190. BRAZIL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY BIOLOGICS, 2025-2030 (USD MILLION)
  • TABLE 191. BRAZIL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 192. BRAZIL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
  • TABLE 193. BRAZIL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 194. BRAZIL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 195. BRAZIL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISEASE CONDITION, 2018-2024 (USD MILLION)
  • TABLE 196. BRAZIL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISEASE CONDITION, 2025-2030 (USD MILLION)
  • TABLE 197. BRAZIL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY GASTROINTESTINAL ISSUES, 2018-2024 (USD MILLION)
  • TABLE 198. BRAZIL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY GASTROINTESTINAL ISSUES, 2025-2030 (USD MILLION)
  • TABLE 199. BRAZIL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 200. BRAZIL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
  • TABLE 201. BRAZIL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 202. BRAZIL COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 203. ARGENTINA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANIMAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 204. ARGENTINA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANIMAL TYPE, 2025-2030 (USD MILLION)
  • TABLE 205. ARGENTINA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 206. ARGENTINA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 207. ARGENTINA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANTIMICROBIALS, 2018-2024 (USD MILLION)
  • TABLE 208. ARGENTINA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANTIMICROBIALS, 2025-2030 (USD MILLION)
  • TABLE 209. ARGENTINA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
  • TABLE 210. ARGENTINA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY BIOLOGICS, 2025-2030 (USD MILLION)
  • TABLE 211. ARGENTINA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 212. ARGENTINA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
  • TABLE 213. ARGENTINA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 214. ARGENTINA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 215. ARGENTINA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISEASE CONDITION, 2018-2024 (USD MILLION)
  • TABLE 216. ARGENTINA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISEASE CONDITION, 2025-2030 (USD MILLION)
  • TABLE 217. ARGENTINA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY GASTROINTESTINAL ISSUES, 2018-2024 (USD MILLION)
  • TABLE 218. ARGENTINA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY GASTROINTESTINAL ISSUES, 2025-2030 (USD MILLION)
  • TABLE 219. ARGENTINA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 220. ARGENTINA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
  • TABLE 221. ARGENTINA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 222. ARGENTINA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 223. EUROPE, MIDDLE EAST & AFRICA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANIMAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 224. EUROPE, MIDDLE EAST & AFRICA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANIMAL TYPE, 2025-2030 (USD MILLION)
  • TABLE 225. EUROPE, MIDDLE EAST & AFRICA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 226. EUROPE, MIDDLE EAST & AFRICA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 227. EUROPE, MIDDLE EAST & AFRICA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANTIMICROBIALS, 2018-2024 (USD MILLION)
  • TABLE 228. EUROPE, MIDDLE EAST & AFRICA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANTIMICROBIALS, 2025-2030 (USD MILLION)
  • TABLE 229. EUROPE, MIDDLE EAST & AFRICA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
  • TABLE 230. EUROPE, MIDDLE EAST & AFRICA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY BIOLOGICS, 2025-2030 (USD MILLION)
  • TABLE 231. EUROPE, MIDDLE EAST & AFRICA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 232. EUROPE, MIDDLE EAST & AFRICA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
  • TABLE 233. EUROPE, MIDDLE EAST & AFRICA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 234. EUROPE, MIDDLE EAST & AFRICA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 235. EUROPE, MIDDLE EAST & AFRICA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISEASE CONDITION, 2018-2024 (USD MILLION)
  • TABLE 236. EUROPE, MIDDLE EAST & AFRICA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISEASE CONDITION, 2025-2030 (USD MILLION)
  • TABLE 237. EUROPE, MIDDLE EAST & AFRICA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY GASTROINTESTINAL ISSUES, 2018-2024 (USD MILLION)
  • TABLE 238. EUROPE, MIDDLE EAST & AFRICA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY GASTROINTESTINAL ISSUES, 2025-2030 (USD MILLION)
  • TABLE 239. EUROPE, MIDDLE EAST & AFRICA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 240. EUROPE, MIDDLE EAST & AFRICA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
  • TABLE 241. EUROPE, MIDDLE EAST & AFRICA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 242. EUROPE, MIDDLE EAST & AFRICA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 243. EUROPE, MIDDLE EAST & AFRICA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 244. EUROPE, MIDDLE EAST & AFRICA COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 245. UNITED KINGDOM COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANIMAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 246. UNITED KINGDOM COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANIMAL TYPE, 2025-2030 (USD MILLION)
  • TABLE 247. UNITED KINGDOM COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 248. UNITED KINGDOM COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 249. UNITED KINGDOM COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANTIMICROBIALS, 2018-2024 (USD MILLION)
  • TABLE 250. UNITED KINGDOM COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANTIMICROBIALS, 2025-2030 (USD MILLION)
  • TABLE 251. UNITED KINGDOM COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
  • TABLE 252. UNITED KINGDOM COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY BIOLOGICS, 2025-2030 (USD MILLION)
  • TABLE 253. UNITED KINGDOM COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 254. UNITED KINGDOM COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
  • TABLE 255. UNITED KINGDOM COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 256. UNITED KINGDOM COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 257. UNITED KINGDOM COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISEASE CONDITION, 2018-2024 (USD MILLION)
  • TABLE 258. UNITED KINGDOM COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISEASE CONDITION, 2025-2030 (USD MILLION)
  • TABLE 259. UNITED KINGDOM COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY GASTROINTESTINAL ISSUES, 2018-2024 (USD MILLION)
  • TABLE 260. UNITED KINGDOM COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY GASTROINTESTINAL ISSUES, 2025-2030 (USD MILLION)
  • TABLE 261. UNITED KINGDOM COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 262. UNITED KINGDOM COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
  • TABLE 263. UNITED KINGDOM COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 264. UNITED KINGDOM COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 265. GERMANY COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANIMAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 266. GERMANY COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANIMAL TYPE, 2025-2030 (USD MILLION)
  • TABLE 267. GERMANY COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 268. GERMANY COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 269. GERMANY COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANTIMICROBIALS, 2018-2024 (USD MILLION)
  • TABLE 270. GERMANY COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANTIMICROBIALS, 2025-2030 (USD MILLION)
  • TABLE 271. GERMANY COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
  • TABLE 272. GERMANY COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY BIOLOGICS, 2025-2030 (USD MILLION)
  • TABLE 273. GERMANY COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 274. GERMANY COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY FORMULATION, 2025-2030 (USD MILLION)
  • TABLE 275. GERMANY COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 276. GERMANY COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
  • TABLE 277. GERMANY COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISEASE CONDITION, 2018-2024 (USD MILLION)
  • TABLE 278. GERMANY COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY DISEASE CONDITION, 2025-2030 (USD MILLION)
  • TABLE 279. GERMANY COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY GASTROINTESTINAL ISSUES, 2018-2024 (USD MILLION)
  • TABLE 280. GERMANY COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY GASTROINTESTINAL ISSUES, 2025-2030 (USD MILLION)
  • TABLE 281. GERMANY COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
  • TABLE 282. GERMANY COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
  • TABLE 283. GERMANY COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 284. GERMANY COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
  • TABLE 285. FRANCE COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANIMAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 286. FRANCE COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANIMAL TYPE, 2025-2030 (USD MILLION)
  • TABLE 287. FRANCE COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 288. FRANCE COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
  • TABLE 289. FRANCE COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANTIMICROBIALS, 2018-2024 (USD MILLION)
  • TABLE 290. FRANCE COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY ANTIMICROBIALS, 2025-2030 (USD MILLION)
  • TABLE 291. FRANCE COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY BIOLOGICS, 2018-2024 (USD MILLION)
  • TABLE 292. FRANCE COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY BIOLOGICS, 2025-2030 (USD MILLION)
  • TABLE 293. FRANCE COMPANION ANIMAL PHARMACEUTICALS MARKET SIZE, BY FORMULATION, 201